Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

Price is unknown


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, esophageal, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. In addition, the company offers drugs for hepatocellular and merkel cell carcinoma; antibiotic and anti-inflammatory drugs for infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticides for sea lice in salmon; and antibiotics and vaccines for fish. Further, it provides companion animal products; diabetes mellitus treatment and anthelmintic products for dogs and cats; products to treat fleas, ticks, mosquitoes, and sandflies; horse fertility management products for swine; and dog, cat, and horse vaccines. Additionally, the company offers services and solutions that focus on engagement, clinical, and health analytics. Merck & Co., Inc. has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Almac Discovery Ltd.; Skyhawk Therapeutics, Inc.; Ridgeback Biotherapeutics; Shanghai Junshi Biosciences Co., Ltd.; FUJIFILM Corporation; and Intec Pharma Ltd. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers; and physicians and physician distributors, veterinarians, and animal producers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Equity (BVPS) 19.00
17.64
18.13
17.52
16.20
15.93
16.39
15.91
14.18
12.51
10.57
growth rate -7.2% 2.8% -3.4% -7.5% -1.7% 2.9% -2.9% -10.9% -11.8% -15.5%
Earnings BIT 15,290.00
1,650.00
7,330.00
9,453.00
6,346.00
9,347.00
8,663.00
10,071.00
8,001.00
9,943.00
15,079.00
growth rate -89.2% 344.2% 29.0% -32.9% 47.3% -7.3% 16.3% -20.6% 24.3% 51.7%
Avg.PE 6.44
131.58
18.66
20.41
34.01
13.97
33.38
32.64
58.53
33.41
23.50
growth rate 1,943.2% -85.8% 9.4% 66.6% -58.9% 138.9% -2.2% 79.3% -42.9% -29.7%
ROA 16.20
0.79
5.93
5.84
4.16
11.69
4.44
3.98
2.61
7.30
11.79
growth rate -95.1% 650.6% -1.5% -28.8% 181.0% -62.0% -10.4% -34.4% 179.7% 61.5%
ROE 33.15
1.52
11.49
11.47
8.57
24.22
9.52
9.25
6.43
20.38
37.42
growth rate -95.4% 655.9% -0.2% -25.3% 182.6% -60.7% -2.8% -30.5% 217.0% 83.6%
ROIC 25.83
1.71
9.34
8.94
6.52
16.90
6.74
6.21
4.23
11.80
19.93
growth rate -93.4% 446.2% -4.3% -27.1% 159.2% -60.1% -7.9% -31.9% 179.0% 68.9%
Cur. Ratio 1.80
1.86
2.04
1.90
2.00
1.77
1.55
1.78
1.33
1.17
1.24
growth rate 3.3% 9.7% -6.9% 5.3% -11.5% -12.4% 14.8% -25.3% -12.0% 6.0%
Quick Ratio 1.02
1.25
1.43
1.30
1.38
1.19
1.04
1.24
0.83
0.72
0.78
growth rate 22.6% 14.4% -9.1% 6.2% -13.8% -12.6% 19.2% -33.1% -13.3% 8.3%
Leverage 1.89
1.95
1.93
2.00
2.12
2.02
2.28
2.38
2.56
3.09
3.26
growth rate 3.2% -1.0% 3.6% 6.0% -4.7% 12.9% 4.4% 7.6% 20.7% 5.5%
Balance Sheet Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Acct.Receivable 6,603.00
7,344.00
11,955.00
7,672.00
7,184.00
6,671.00
6,518.00
7,018.00
6,918.00
7,226.00
7,105.00
growth rate 11.2% 62.8% -35.8% -6.4% -7.1% -2.3% 7.7% -1.4% 4.5% -1.7%
Acct.Payable 14,255.00
1,753.00
2,274.00
2,625.00
2,533.00
2,807.00
3,102.00
4,098.00
5,015.00
growth rate -87.7% 29.7% 15.4% -3.5% 10.8% 10.5% 32.1% 22.4%
Cur.Assets 28,432.00
29,064.00
33,181.00
34,857.00
35,685.00
32,605.00
29,751.00
30,614.00
24,766.00
25,875.00
27,483.00
growth rate 2.2% 14.2% 5.1% 2.4% -8.6% -8.8% 2.9% -19.1% 4.5% 6.2%
Total Assets 112,314.00
105,781.00
105,128.00
106,132.00
105,645.00
98,167.00
101,677.00
95,377.00
87,872.00
82,637.00
84,397.00
growth rate -5.8% -0.6% 1.0% -0.5% -7.1% 3.6% -6.2% -7.9% -6.0% 2.1%
Cash 9,311.00
10,900.00
13,531.00
13,451.00
15,621.00
7,441.00
8,524.00
6,515.00
6,092.00
7,965.00
9,676.00
growth rate 17.1% 24.1% -0.6% 16.1% -52.4% 14.6% -23.6% -6.5% 30.8% 21.5%
Inventory 8,048.00
5,868.00
6,254.00
6,535.00
6,226.00
5,571.00
4,700.00
4,866.00
5,096.00
5,440.00
5,978.00
growth rate -27.1% 6.6% 4.5% -4.7% -10.5% -15.6% 3.5% 4.7% 6.8% 9.9%
Cur.Liabilities 15,641.00
15,641.00
16,245.00
18,348.00
17,868.00
18,397.00
19,201.00
17,204.00
18,614.00
22,206.00
22,220.00
growth rate 0.0% 3.9% 13.0% -2.6% 3.0% 4.4% -10.4% 8.2% 19.3% 0.1%
Liabilities 53,256.00
51,405.00
50,611.00
53,112.00
55,880.00
49,376.00
56,910.00
55,069.00
53,303.00
55,755.00
58,396.00
growth rate -3.5% -1.5% 4.9% 5.2% -11.6% 15.3% -3.2% -3.2% 4.6% 4.7%
LT Debt 16,095.00
15,482.00
15,525.00
16,254.00
20,539.00
18,714.00
23,852.00
24,303.00
21,405.00
19,887.00
22,736.00
growth rate -3.8% 0.3% 4.7% 26.4% -8.9% 27.5% 1.9% -11.9% -7.1% 14.3%
Equity 59,058.00
54,376.00
54,517.00
53,020.00
49,765.00
48,647.00
44,676.00
40,088.00
34,336.00
26,701.00
25,907.00
growth rate -7.9% 0.3% -2.8% -6.1% -2.3% -8.2% -10.3% -14.4% -22.2% -3.0%
Common Shares 2,273.00
3,120.00
3,094.00
3,076.00
2,996.00
2,928.00
2,841.00
2,787.00
2,748.00
2,679.00
2,580.00
growth rate 37.3% -0.8% -0.6% -2.6% -2.3% -3.0% -1.9% -1.4% -2.5% -3.7%
Cash Flow Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Capital Expenditures 0.00
0.00
1,723.00
1,954.00
1,548.00
1,317.00
1,283.00
1,614.00
1,888.00
2,615.00
3,473.00
growth rate 13.4% -20.8% -14.9% -2.6% 25.8% 17.0% 38.5% 32.8%
Cash Dividends 3,479.00
4,853.00
4,691.00
5,236.00
5,277.00
5,170.00
5,117.00
5,124.00
5,167.00
5,172.00
5,695.00
growth rate 39.5% -3.3% 11.6% 0.8% -2.0% -1.0% 0.1% 0.8% 0.1% 10.1%
Cash From OA 3,392.00
10,822.00
12,383.00
10,022.00
11,654.00
7,989.00
12,538.00
10,376.00
6,451.00
10,922.00
13,440.00
growth rate 219.0% 14.4% -19.1% 16.3% -31.5% 56.9% -17.2% -37.8% 69.3% 23.1%
FCF per Share 0.85
2.93
3.51
2.62
2.82
3.66
1.65
3.33
1.57
3.31
3.45
growth rate 244.7% 19.8% -25.4% 7.6% 29.8% -54.9% 101.8% -52.9% 110.8% 4.2%
Sale Purchase of Stock -1,720.00
-2,591.00
-6,516.00
1,560.00
485.00
939.00
-3,515.00
growth rate 0.0% 0.0% 100.0% -68.9% 93.6% -100.0%
FCF 1,931.00
9,144.00
10,660.00
8,068.00
10,106.00
5,543.00
11,138.00
8,762.00
4,559.00
8,307.00
9,967.00
growth rate 373.5% 16.6% -24.3% 25.3% -45.2% 100.9% -21.3% -48.0% 82.2% 20.0%
Income Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Sales 27,428.00
45,987.00
48,047.00
47,267.00
44,033.00
42,237.00
39,498.00
39,807.00
40,122.00
42,294.00
46,840.00
growth rate 67.7% 4.5% -1.6% -6.8% -4.1% -6.5% 0.8% 0.8% 5.4% 10.8%
Op.Income 2,387.00
2,370.00
6,882.00
6,299.00
4,517.00
9,347.00
8,663.00
10,071.00
8,001.00
9,943.00
15,079.00
growth rate -0.7% 190.4% -8.5% -28.3% 106.9% -7.3% 16.3% -20.6% 24.3% 51.7%
IBT 15,290.00
1,653.00
7,334.00
8,739.00
5,545.00
17,283.00
5,401.00
4,659.00
6,521.00
8,701.00
11,464.00
growth rate -89.2% 343.7% 19.2% -36.6% 211.7% -68.8% -13.7% 40.0% 33.4% 31.8%
Net Income 12,899.00
861.00
6,882.00
6,168.00
4,404.00
11,920.00
4,442.00
3,920.00
2,394.00
6,220.00
9,843.00
growth rate -93.3% 699.3% -10.4% -28.6% 170.7% -62.7% -11.8% -38.9% 159.8% 58.3%
EPS 5.65
0.28
2.02
2.00
1.47
4.07
1.56
1.41
0.87
2.32
3.81
growth rate -95.0% 621.4% -1.0% -26.5% 176.9% -61.7% -9.6% -38.3% 166.7% 64.2%
Gross Profit 18,409.00
27,591.00
31,176.00
37,799.00
27,079.00
27,051.00
25,075.00
26,305.00
27,406.00
28,806.00
33,684.00
growth rate 49.9% 13.0% 21.2% -28.4% -0.1% -7.3% 4.9% 4.2% 5.1% 16.9%
R&D 5,845.00
11,111.00
8,467.00
8,168.00
7,503.00
6,532.00
6,613.00
6,921.00
9,845.00
9,308.00
8,742.00
growth rate 90.1% -23.8% -3.5% -8.1% -12.9% 1.2% 4.7% 42.3% -5.5% -6.1%

Quarterly Statements

Item Name Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Earnings BIT 3,980.00
4,443.00
3,192.00
4,200.00
3,421.00
growth rate 11.6% -28.2% 31.6% -18.6%
Balance Sheet Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Acct.Receivable 8,208.00
8,714.00
7,105.00
8,514.00
7,980.00
growth rate 6.2% -18.5% 19.8% -6.3%
Acct.Payable 4,456.00
4,468.00
5,015.00
4,323.00
4,097.00
growth rate 0.3% 12.2% -13.8% -5.2%
Cur.Assets 24,298.00
26,142.00
27,483.00
26,174.00
29,343.00
growth rate 7.6% 5.1% -4.8% 12.1%
Total Assets 83,965.00
83,331.00
84,397.00
84,913.00
90,615.00
growth rate -0.8% 1.3% 0.6% 6.7%
Cash 6,659.00
7,869.00
9,676.00
7,425.00
11,103.00
growth rate 18.2% 23.0% -23.3% 49.5%
Inventory 5,847.00
5,855.00
5,978.00
5,846.00
6,056.00
growth rate 0.1% 2.1% -2.2% 3.6%
Cur.Liabilities 20,085.00
20,684.00
22,220.00
23,483.00
22,178.00
growth rate 3.0% 7.4% 5.7% -5.6%
Liabilities 56,228.00
56,406.00
58,396.00
58,613.00
62,871.00
growth rate 0.3% 3.5% 0.4% 7.3%
LT Debt 22,773.00
22,677.00
22,736.00
21,637.00
26,156.00
growth rate -0.4% 0.3% -4.8% 20.9%
Equity 27,635.00
26,838.00
25,907.00
26,205.00
27,642.00
growth rate -2.9% -3.5% 1.2% 5.5%
Common Shares 1,788.00
1,788.00
1,788.00
1,788.00
1,788.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Capital Expenditures 782.00
959.00
1,137.00
986.00
668.00
growth rate 22.6% 18.6% -13.3% -32.3%
Cash Dividends 1,468.00
1,394.00
1,405.00
1,551.00
1,577.00
growth rate -5.0% 0.8% 10.4% 1.7%
Cash From OA 3,084.00
4,226.00
4,794.00
707.00
3,367.00
growth rate 37.0% 13.4% -85.3% 376.2%
Sale Purchase of Stock
growth rate
FCF 2,302.00
3,267.00
3,657.00
-279.00
2,699.00
growth rate 41.9% 11.9% -100.0% 100.0%
Income Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Sales 11,760.00
12,397.00
11,868.00
12,057.00
10,872.00
growth rate 5.4% -4.3% 1.6% -9.8%
Op.Income 3,980.00
4,443.00
3,192.00
4,200.00
3,421.00
growth rate 11.6% -28.2% 31.6% -18.6%
IBT 3,259.00
2,347.00
2,791.00
3,838.00
3,519.00
growth rate -28.0% 18.9% 37.5% -8.3%
Net Income 2,670.00
1,901.00
2,356.00
3,219.00
3,002.00
growth rate -28.8% 23.9% 36.6% -6.7%
EPS
growth rate
Gross Profit 8,493.00
9,081.00
8,301.00
8,813.00
7,738.00
growth rate 6.9% -8.6% 6.2% -12.2%
R&D 2,186.00
2,221.00
2,368.00
2,159.00
2,174.00
growth rate 1.6% 6.6% -8.8% 0.7%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

D (33.54)

YOY Growth Grade:

F (12.59)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 19.34 19.34 12.54
EPS / Growth 8.7% 4.10 6.7%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 5.4% 5.4%
Future PE 2.00 14.25 14.25
Future EPS 4.53 6.97 6.97
Value Price
MOS %
2.24
24.56
24.56
MOS Price 1.12 12.28 12.28
IRT

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.